Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model.

Bresson D, von Herrath MG.

Clin Exp Immunol. 2011 Mar;163(3):375-80. doi: 10.1111/j.1365-2249.2010.04304.x. Epub 2011 Jan 14.

2.
3.

CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes.

Fousteri G, Dave A, Juntti T, von Herrath M.

J Autoimmun. 2009 Feb;32(1):70-7. doi: 10.1016/j.jaut.2008.12.001. Epub 2009 Jan 21.

4.

In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.

von Herrath MG, Coon B, Lewicki H, Mazarguil H, Gairin JE, Oldstone MB.

J Immunol. 1998 Nov 1;161(9):5087-96.

8.
9.

Enhanced T cell responses contribute to the genetic predisposition of CD8-mediated spontaneous autoimmunity.

Garza KM, McKall-Faienza KJ, Otheki T, Zakarian A, Odermatt B, Ohashi PS.

Eur J Immunol. 2002 Mar;32(3):885-94.

10.

The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.

Boettler T, Pagni PP, Jaffe R, Cheng Y, Zerhouni P, von Herrath M.

J Autoimmun. 2013 Aug;44:40-8. doi: 10.1016/j.jaut.2013.05.002. Epub 2013 Jun 13.

11.

Absence of TNFRp55 influences virus-induced autoimmunity despite efficient lymphocytic infiltration.

McKall-Faienza KJ, Kawai K, Kündig TM, Odermatt B, Bachmann MF, Zakarian A, Mak TW, Ohashi PS.

Int Immunol. 1998 Apr;10(4):405-12.

PMID:
9620596
12.
13.

IGRP and insulin vaccination induce CD8+ T cell-mediated autoimmune diabetes in the RIP-CD80GP mouse.

Fuchs YF, Adler K, Lindner A, Karasinsky A, Wilhelm C, Weigelt M, Balke H, Förtsch K, Mortler-Hildebrandt LF, Harlan DM, Pechhold K, Ziegler AG, Bonifacio E.

Clin Exp Immunol. 2014 May;176(2):199-206. doi: 10.1111/cei.12263.

14.
15.

PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.

Fousteri G, Jofra T, Di Fonte R, Kuka M, Iannacone M, Battaglia M.

Clin Immunol. 2015 Feb;156(2):98-108. doi: 10.1016/j.clim.2014.12.002. Epub 2014 Dec 13.

PMID:
25513733
16.

Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-alpha.

Ohashi PS, Oehen S, Aichele P, Pircher H, Odermatt B, Herrera P, Higuchi Y, Buerki K, Hengartner H, Zinkernagel RM.

J Immunol. 1993 Jun 1;150(11):5185-94.

PMID:
8496610
17.

NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes.

Van Belle TL, Ling E, Haase C, Bresson D, Ursø B, von Herrath MG.

J Autoimmun. 2013 Feb;40:66-73. doi: 10.1016/j.jaut.2012.08.001. Epub 2012 Sep 1.

PMID:
22944096
18.

Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection.

Oxenius A, Bachmann MF, Zinkernagel RM, Hengartner H.

Eur J Immunol. 1998 Jan;28(1):390-400.

PMID:
9485218
19.

Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model.

Christen S, Holdener M, Beerli C, Thoma G, Bayer M, Pfeilschifter JM, Hintermann E, Zerwes HG, Christen U.

Clin Exp Immunol. 2011 Sep;165(3):318-28. doi: 10.1111/j.1365-2249.2011.04426.x. Epub 2011 Jun 7.

Supplemental Content

Support Center